Cancer Immunology – News and Features

The agreement aims at developing and commercializing Cell Genesys' GVAX immunotherapy for prostate cancer.

Researchers have shown that vaccinating mice with a modified form of a virus containing proteins from breast cancer cells can kill large breast cancer tumors and tumors that have spread to the lungs.

In experiments with mice, researchers have found that the body's immune system can use a surprisingly common molecule to recognize prostate tumors.

Two companies have entered into an asset sale agreement relating to Cell Genesys' lentiviral gene delivery technology.

Idera has agreed to exclusively license the therapeutic oncology applications, excluding cancer vaccines, of its lead TLR9 agonists.

Gene therapy treatment aimed to boost immune system to fight deadly disease.

The acquisition will bring together IVT's signature VacciMax® platform with Immunotope's portfolio of immunotherapeutic antigens and antigen discovery platform.

Investigators have discovered a new signaling molecule that prevents immune responses from running amok and damaging the body.

Company expanding R&D to advance its DNA delivery technology and develop proprietary DNA vaccines for cancer and chronic infectious diseases.

Data from a clinical study of DNA-based prostrate cancer demonstrated that Inovio’s DNA delivery technology enhanced the potency of the gene-based vaccine.